Tanaka Katsunori, Albin Monica J, Yuan Xueli, Yamaura Kazuhiro, Habicht Antje, Murayama Takaya, Grimm Martin, Waaga Ana Maria, Ueno Takuya, Padera Robert F, Yagita Hideo, Azuma Miyuki, Shin Tahiro, Blazar Bruce R, Rothstein David M, Sayegh Mohamed H, Najafian Nader
Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Immunol. 2007 Oct 15;179(8):5204-10. doi: 10.4049/jimmunol.179.8.5204.
The PD-1:PDL pathway plays an important role in regulating alloimmune responses but its role in transplantation tolerance is unknown. We investigated the role of PD-1:PDL costimulatory pathway in peripheral and a well established model of central transplantation tolerance. Early as well as delayed blockade of PDL1 but not PDL2 abrogated tolerance induced by CTLA4Ig in a fully MHC-mismatched cardiac allograft model. Accelerated rejection was associated with a significant increase in the frequency of IFN-gamma-producing alloreactive T cells and expansion of effector CD8(+) T cells in the periphery, and a decline in the percentage of Foxp3(+) graft infiltrating cells. Similarly, studies using PDL1/L2-deficient recipients confirmed the results with Ab blockade. Interestingly, while PDL1-deficient donor allografts were accepted by wild-type recipients treated with CTLA4Ig, the grafts developed severe chronic rejection and vasculopathy when compared with wild-type grafts. Finally, in a model of central tolerance induced by mixed allogeneic chimerism, engraftment was not abrogated by PDL1/L2 blockade. These novel data demonstrate the critical role of PDL1 for induction and maintenance of peripheral transplantation tolerance by its ability to alter the balance between pathogenic and regulatory T cells. Expression of PDL1 in donor tissue is critical for prevention of in situ graft pathology and chronic rejection.
PD-1:PDL通路在调节同种异体免疫反应中起重要作用,但其在移植耐受中的作用尚不清楚。我们研究了PD-1:PDL共刺激通路在周围及成熟的中枢移植耐受模型中的作用。在完全MHC不匹配的心脏同种异体移植模型中,早期及延迟阻断PDL1而非PDL2可消除CTLA4Ig诱导的耐受。加速排斥反应与外周产生IFN-γ的同种异体反应性T细胞频率显著增加及效应性CD8(+) T细胞扩增有关,同时Foxp3(+)移植物浸润细胞百分比下降。同样,使用PDL1/L2缺陷受体的研究证实了抗体阻断的结果。有趣的是,虽然PDL1缺陷的供体同种异体移植物被接受CTLA4Ig治疗的野生型受体所接受,但与野生型移植物相比,这些移植物发生了严重的慢性排斥反应和血管病变。最后,在混合同种异体嵌合体诱导的中枢耐受模型中,PDL1/L2阻断并未消除植入。这些新数据表明,PDL1通过改变致病性T细胞和调节性T细胞之间的平衡,在诱导和维持外周移植耐受中起关键作用。供体组织中PDL1的表达对于预防原位移植物病理和慢性排斥反应至关重要。